JAC Advance Access originally published online on March 10, 2006
Journal of Antimicrobial Chemotherapy 2006 57(5):970-974; doi:10.1093/jac/dkl081
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-ß-naphthylamide
1 Center for Infectious Diseases and Travel Medicine, University Hospital, Freiburg, Germany; 2 Institute of Medical Microbiology, Immunology and Hygiene, University Hospital, Köln, Germany; 3 Institute of Environmental Medicine and Hospital Epidemiology, University Hospital, Freiburg, Germany; 4 Section of Infectious Diseases, Hacettepe University, Ankara, Turkey
Received 6 December 2005; returned 8 January 2006; revised 7 February 2006; accepted 22 February 2006
* Correspondence address: Medizinische Universitätsklinik, Hugstetter Strasse 55, D-79106 Freiburg, Germany. Tel: +49-761-270-1819; Fax: +49-761-270-1820; E-mail: kern{at}if-freiburg.de
Objectives: 1-(1-Naphthylmethyl)-piperazine (NMP) has been shown to reverse multidrug resistance (MDR) in Escherichia coli overexpressing RND-type efflux pumps but there are no data on its activity in non-fermenters like Acinetobacter.
Methods: Antimicrobial susceptibility in the absence and presence of NMP and, for comparison, phenyl-arginine-ß-naphthylamide (PAßN), another putative efflux pump inhibitor (EPI), was tested in laboratory and mutant strains with differing intracellular dye accumulation and expression of adeB, and in clinical isolates of Acinetobacter baumannii.
Results: Based on a 4-fold or greater MIC reduction, the effects of both EPIs at low concentrations (25 mg/L) were limited. PAßN had a highly selective action on the reduction in the MIC of rifampicin and clarithromycin. At a higher concentration of the putative EPIs (100 mg/L), NMP was more active than PAßN. This effect was not limited to strains with adeB overexpression, but affected the susceptibility to linezolid, chloramphenicol and tetracycline most, and was enhanced in clinical isolates with reduced fluoroquinolone susceptibility.
Conclusion: NMP can partially reverse MDR in A. baumannii and differs substantially in its activity from that of PAßN.
Keywords: multidrug resistance , fluoroquinolones , nosocomial pathogens
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. J. Vecchione, B. Alexander Jr., and J. K. Sello Two Distinct Major Facilitator Superfamily Drug Efflux Pumps Mediate Chloramphenicol Resistance in Streptomyces coelicolor Antimicrob. Agents Chemother., November 1, 2009; 53(11): 4673 - 4677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chusri, I. Villanueva, S. P. Voravuthikunchai, and J. Davies Enhancing antibiotic activity: a strategy to control Acinetobacter infections J. Antimicrob. Chemother., October 27, 2009; (2009) dkp381v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Chen, B. Pi, H. Zhou, Y. Yu, and L. Li Triclosan resistance in clinical isolates of Acinetobacter baumannii J. Med. Microbiol., August 1, 2009; 58(8): 1086 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Bean and D. W. Wareham Paradoxical effect of 1-(1-naphthylmethyl)-piperazine on resistance to tetracyclines in multidrug-resistant Acinetobacter baumannii J. Antimicrob. Chemother., February 1, 2009; 63(2): 349 - 352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. R. Bina, J. A. Philippart, and J. E. Bina Effect of the efflux inhibitors 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-{beta}-naphthylamide on antimicrobial susceptibility and virulence factor production in Vibrio cholerae J. Antimicrob. Chemother., January 1, 2009; 63(1): 103 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bratu, D. Landman, D. A. Martin, C. Georgescu, and J. Quale Correlation of Antimicrobial Resistance with {beta}-Lactamases, the OmpA-Like Porin, and Efflux Pumps in Clinical Isolates of Acinetobacter baumannii Endemic to New York City Antimicrob. Agents Chemother., September 1, 2008; 52(9): 2999 - 3005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Valentine, D. Contreras, S. Tan, L. J. Real, S. Chu, and H. H. Xu Phenotypic and Molecular Characterization of Acinetobacter baumannii Clinical Isolates from Nosocomial Outbreaks in Los Angeles County, California J. Clin. Microbiol., August 1, 2008; 46(8): 2499 - 2507. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hannula and M.-L. Hanninen Effect of putative efflux pump inhibitors and inducers on the antimicrobial susceptibility of Campylobacter jejuni and Campylobacter coli J. Med. Microbiol., July 1, 2008; 57(7): 851 - 855. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Perichon, P. Courvalin, and M. Galimand Transferable Resistance to Aminoglycosides by Methylation of G1405 in 16S rRNA and to Hydrophilic Fluoroquinolones by QepA-Mediated Efflux in Escherichia coli Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2464 - 2469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schumacher, R. Trittler, J. A. Bohnert, K. Kummerer, J.-M. Pages, and W. V. Kern Intracellular accumulation of linezolid in Escherichia coli, Citrobacter freundii and Enterobacter aerogenes: role of enhanced efflux pump activity and inactivation J. Antimicrob. Chemother., June 1, 2007; 59(6): 1261 - 1264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mahamoud, J. Chevalier, S. Alibert-Franco, W. V. Kern, and J.-M. Pages Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy J. Antimicrob. Chemother., June 1, 2007; 59(6): 1223 - 1229. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Y. Peleg, J. Adams, and D. L. Paterson Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii Antimicrob. Agents Chemother., June 1, 2007; 51(6): 2065 - 2069. [Abstract] [Full Text] [PDF]
|
|